Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) shares were down 7.4% during mid-day trading on Wednesday . The company traded as low as $3.21 and last traded at $3.23. Approximately 1,041,498 shares traded hands during mid-day trading, a decline of 5% from the average daily volume of 1,093,399 shares. The stock had previously closed at $3.49.
A number of research analysts have issued reports on TTPH shares. HC Wainwright reiterated a “buy” rating on shares of Tetraphase Pharmaceuticals in a research report on Monday, July 16th. WBB Securities upgraded Tetraphase Pharmaceuticals from a “speculative buy” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Thursday. Zacks Investment Research cut Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. ValuEngine lowered Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 30th. Finally, B. Riley lifted their price target on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, August 28th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $6.41.
The stock has a market cap of $170.73 million, a P/E ratio of -1.26 and a beta of 2.65.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.18. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%. The company had revenue of $11.58 million during the quarter, compared to analysts’ expectations of $2.23 million. equities analysts forecast that Tetraphase Pharmaceuticals Inc will post -1.38 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. increased its position in shares of Tetraphase Pharmaceuticals by 3.7% in the second quarter. BlackRock Inc. now owns 4,172,314 shares of the biopharmaceutical company’s stock worth $14,895,000 after acquiring an additional 149,866 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Tetraphase Pharmaceuticals by 20.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,200,413 shares of the biopharmaceutical company’s stock worth $7,855,000 after purchasing an additional 367,672 shares during the last quarter. Candriam Luxembourg S.C.A. grew its stake in shares of Tetraphase Pharmaceuticals by 3.1% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 520,613 shares of the biopharmaceutical company’s stock worth $1,598,000 after purchasing an additional 15,613 shares during the last quarter. UBS Group AG acquired a new position in shares of Tetraphase Pharmaceuticals in the 1st quarter worth approximately $1,130,000. Finally, Millennium Management LLC grew its stake in shares of Tetraphase Pharmaceuticals by 129.7% in the 2nd quarter. Millennium Management LLC now owns 297,942 shares of the biopharmaceutical company’s stock worth $1,064,000 after purchasing an additional 168,253 shares during the last quarter. Institutional investors own 40.94% of the company’s stock.
Tetraphase Pharmaceuticals Company Profile (NASDAQ:TTPH)
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Featured Story: Market Capitalization
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.